利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.023 秒)

    TNF-muteins
    1.
    发明授权
    TNF-muteins 失效
    TNF-突变蛋白

    公开(公告)号：US5422104A

    公开(公告)日：1995-06-06

    申请号：US794400

    申请日：1991-11-20

    申请人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    发明人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N1/21 ,  C12N15/09 ,  C12N15/28 ,  C12P21/02 ,  C12R1/19 ,  A61K45/05 ,  C12P21/06

    CPC分类号： C07K14/525 ,  A61K38/00

    摘要： It is an object of this invention to provide a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof characterized in that the TNF sequence is changed by a deletion, insertion, substitution or combinations thereof, of one or more amino acids so that the mutein shows a significant difference between its binding affinity to the human p75-Tumor-Necrosis-Factor-Receptor and to the human p55-Tumor-Necrosis-Factor-Receptor. The invention also includes DNA sequences coding for such muteins, vectors comprising such DNA sequences, host cells transformed with such vectors and a process for the production of such muteins employing such transformed host cells and pharmaceutical compositions containing such muteins and their use for the treatment of illnesses, for example cancer.

    摘要翻译： 本发明的目的是提供一种人肿瘤坏死因子突变蛋白或其药学上可接受的盐，其特征在于通过其一个或多个氨基酸的缺失，插入，取代或组合改变TNF序列，使得突变蛋白 显示其与人p75-肿瘤坏死因子受体和人p55-肿瘤坏死因子受体的结合亲和力之间的显着差异。 本发明还包括编码这种突变蛋白的DNA序列，包含这种DNA序列的载体，用这种载体转化的宿主细胞和使用这种转化的宿主细胞产生这种突变蛋白的方法和含有这种突变蛋白的药物组合物及其用于治疗 疾病，例如癌症。

    DNAs encoding tumor necrosis factor-.alpha. muteins
    2.
    发明授权
    DNAs encoding tumor necrosis factor-.alpha. muteins 失效
    编码肿瘤坏死因子-α突变蛋白的DNA

    公开(公告)号：US5652353A

    公开(公告)日：1997-07-29

    申请号：US397470

    申请日：1995-03-01

    申请人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    发明人： Walter Fiers ,  Jan Tavernier ,  Xaveer Van Ostade

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/525 ,  C12N1/21 ,  C12N15/09 ,  C12N15/28 ,  C12P21/02 ,  C12R1/19

    CPC分类号： C07K14/525 ,  A61K38/00

    摘要： It is an object of this invention to provide a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof characterized in that the TNF sequence is changed by a deletion, insertion, substitution or combinations thereof, of one or more amino acids so that the mutein shows a significant difference between its binding affinity to the human p75-Tumor-Necrosis-Factor-Receptor and to the human p55-Tumor-Necrosis-Factor-Receptor. The invention also includes DNA sequences coding for such muteins, vectors comprising such DNA sequences, host cells transformed with such vectors and a process for the production of such muteins employing such transformed host cells and pharmaceutical compositions containing such muteins and their use for the treatment of illnesses, for example cancer.

    摘要翻译： 本发明的目的是提供一种人肿瘤坏死因子突变蛋白或其药学上可接受的盐，其特征在于通过其一个或多个氨基酸的缺失，插入，取代或组合改变TNF序列，使得突变蛋白 显示其与人p75-肿瘤坏死因子受体和人p55-肿瘤坏死因子受体的结合亲和力之间的显着差异。 本发明还包括编码这种突变蛋白的DNA序列，包含这种DNA序列的载体，用这种载体转化的宿主细胞和使用这种转化的宿主细胞产生这种突变蛋白的方法和含有这种突变蛋白的药物组合物及其用于治疗 疾病，例如癌症。

    KINASE SUBSTRATE SENSOR
    9.
    发明申请
    KINASE SUBSTRATE SENSOR 审中-公开
    激光基底传感器

    公开(公告)号：US20140030746A1

    公开(公告)日：2014-01-30

    申请号：US14002320

    申请日：2012-02-29

    申请人： Jan Tavernier ,  Samuel Lievens

    发明人： Jan Tavernier ,  Samuel Lievens

    IPC分类号： C12Q1/48 ,  C12N9/12

    CPC分类号： C12N9/12 ,  C07K2319/00 ,  C12N15/1055 ,  C12N15/62 ,  C12Q1/485 ,  G01N33/542

    摘要： The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.

    摘要翻译： 本公开涉及细胞质蛋白复合物，其包含：（a）包含与第一相互作用多肽融合的激酶的第一重组融合蛋白; 和（b）第二重组融合蛋白，其包含包含报告基因磷酸化位点的结构域，其中所述结构域与第二相互作用多肽融合。 本公开进一步涉及使用细胞质蛋白复合物检测化合物 - 相互作用的方法，以及包含这种细胞质蛋白复合物的细胞。

    Reversed mammalian protein-protein interaction trap
    10.
    发明申请
    Reversed mammalian protein-protein interaction trap 有权
    反转的哺乳动物蛋白质 - 蛋白质相互作用陷阱

    公开(公告)号：US20100174049A1

    公开(公告)日：2010-07-08

    申请号：US12653513

    申请日：2009-12-14

    申请人： Sven Eyckerman ,  Jan Tavernier ,  Joël Vandkerckhove

    发明人： Sven Eyckerman ,  Jan Tavernier ,  Joël Vandkerckhove

    IPC分类号： C07K14/00

    CPC分类号： C07K14/705 ,  C07K14/4703 ,  C07K14/4718 ,  C07K2319/00 ,  C12N15/1055

    摘要： The invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The invention also relates to a method of screening compounds that disrupt compound-compound binding using the recombinant receptor.

    摘要翻译： 本发明涉及重组受体，其包含配体结合结构域和包含异源诱饵多肽的信号结构域，所述诱饵多肽在存在或不存在配体结合的情况下通过将猎物多肽与异源诱饵肽结合而失活 到配体结合结构域。 通过加入扰乱诱饵 - 捕食相互作用的化合物来激活受体。 本发明还涉及一种筛选使用重组受体破坏化合物 - 化合物结合的化合物的方法。